Axsome 3rd Quarter Financial Results

Axsome released their third quarter financial results on Monday. Just a few highlights from the just completed impressive quarter, are below. 

• Auvelity for MDD sales totaled $37.7 million for the quarter
• Sunosi for narcolepsy sales totaled $20.1 million for the quarter
• $417 million in cash on hand, end of quarter
• AXS-12 clinical trial for cataplexy, to read out in the first quarter, 2024
• AXS-05 clinical trial for Alzheimer's Disease Agitation, complete first half of 2024

Below is up to date, weekly prescriptions of Auvelity for MDD. Thank you for reading.